Functionally, GO enrichment revealed broad genomic differential expression across hundreds of biological processes, pointing towards systematic changes during CML progression in consequence of BCR-ABL signalling, rather than deregulation of a single or defined set of signalling pathways. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.